Previous 10 | Next 10 |
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the H.C. Wainwright 23 rd Annual Global Investment Conference. The pre...
UroGen Pharma Ltd. (URGN) Q2 2021 Earnings Conference Call August 4, 2021 8:30 a.m. ET Company Participants Sara Sherman - Head of Investor Relations Liz Barrett - President and CEO Jeff Bova - Chief Commercial Officer Mark Schoenberg - Chief Medical Officer Molly Henderson - CFO Conference C...
UroGen Pharma (NASDAQ:URGN): Q2 GAAP EPS of -$1.17 in-line. Revenue of $13.03M (+3421.6% Y/Y) beats by $1.38M. Press Release For further details see: UroGen Pharma EPS in-line, beats on revenue
Strong Jelmyto® net product revenue of $13.0 million for the second quarter of 2021, representing more than 70% growth over the first quarter of 2021 Nearly 100 global centers activated for Phase 3 landmark ATLAS trial with lead pipeline candidate, UGN-102 Comme...
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Elizabeth (Liz) Barre...
UroGen Pharma (URGN) announces an exclusive license for Neopharm to market and sell Jelmyto (mitomycin) for pyelocalyceal solution in Israel, subject to regulatory approval. Jelmyto is the first and only U.S. FDA approved medicine for adult patients with low-grade upper tr...
Jelmyto ® granted expedited review in Israel Jelmyto is the only US FDA approved treatment for low-grade upper tract urothelial cancer UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solution...
Conference Call and Webcast Scheduled for Wednesday, August 4, 2021 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that...
The following slide deck was published by UroGen Pharma Ltd. in conjunction with this event. For further details see: UroGen Pharma (URGN) Presents At HealthVirtual Conference - Slideshow
UroGen Pharma (URGN) expects net product revenue from Jelmyto sales for Q2 ended June 30, 2021, to be ~$13M (consensus $10.46M).Operating expenses are anticipated to be in the range of $33M-$38M.Cash and equivalents as of June 30, 2021, are expected to be ~$129M. “Our strong, prelimina...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...